What is TrialNet?
TrialNet is an international network of researchers dedicated to the study, prevention and early treatment of type 1 diabetes. TrialNet has clinical centers in the United States, Canada, Europe, and Australia.
 
TrialNet conducts studies to:
  • Learn more about the factors that put some people at risk for developing diabetes,
  • Test treatments that could help delay or prevent diabetes, and
  • Test treatments that might help people keep producing their own insulin when they are first diagnosed with diabetes.
Who Supports TrialNet?

TrialNet is primarily supported by the Department of Health and Human Services, National Institutes of Health, JDRF International, National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, The National Institute of Child Health and Human Development, and the American Diabetes Association.

        

 
To be notified about new TrialNet studies and study results, subscribe to the TrialNet e-newsletter. Past issues are available here.